GKOS250117P140000
- 2.10
- +0.60+40.00%
Glaukos Newsroom
This Glaukos Insider Reduced Their Stake By 56%
Here's Why You Should Add Glaukos Stock to Your Portfolio Now
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $157
BTIG Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $157
Express News | Glaukos Corp : Btig Raises Target Price to $157 From $149
BTIG Sticks to Its Buy Rating for Glaukos (GKOS)
Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $175
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $175
(GKOS) - Analyzing Glaukos's Short Interest
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
Glaukos Insider Sold Shares Worth $1,502,800, According to a Recent SEC Filing
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Express News | Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
The Three-year Returns Have Been Stellar for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?
Stifel Maintains Glaukos(GKOS.US) With Buy Rating, Maintains Target Price $153
NYSE New 52-Week Highs And Lows
Glaukos (GKOS) Receives a Buy From Stifel Nicolaus
Truist Financial Maintains Glaukos(GKOS.US) With Buy Rating, Announces Target Price $185